ASCO 2023 | The benefits of next-generation sequencing in managing brain tumors

Patrick Wen, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the role of next-generation sequencing (NGS) in brain tumor management. Sequencing tumors has enabled more enhanced classification of brain tumors, leading to identification of patients who will benefit from certain therapies. Rare subsets of glioma have additionally been identified, where they are eligible for targeted therapies, such as the BRAF V600E inhibitors dabrafenib and trametinib. NTRK fusions are also potential targets in the future. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.